The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys

Behav Pharmacol. 2002 Dec;13(8):639-44. doi: 10.1097/01.fbp.0000047148.28986.67.

Abstract

The adenosine A2A receptor agonist CGS 21680 has shown effects similar to dopamine antagonists in behavioural assays in rats predictive for antipsychotic activity, without induction of extrapyramidal side-effects (EPS). In the present study, we examined whether this functional dopamine antagonism and lack of EPS in rodents could also be observed in non-human primates. We investigated the effects of CGS 21680 on behaviours induced by D-amphetamine and (-)-apomorphine in EPS-sensitized Cebus apella monkeys. CGS 21680 was administered s.c. in doses of 0.01, 0.025 and 0.05 mg/kg, alone and in combination with D-amphetamine and (-)-apomorphine. The monkeys were videotaped after drug administration and the tapes were rated for EPS and psychosis-like symptoms. CGS 21680 decreased apomorphine-induced behavioural unrest, arousal (0.01-0.05 mg/kg) and stereotypies (0.05 mg/kg) while amphetamine-induced behaviours (unrest, stereotypies, arousal) were unaffected. EPS were not observed at any dose. At 0.05 mg/kg CGS 21680 produced vomiting. The two lower doses did not produce observable side-effects. Though the differential effect on amphetamine- and apomorphine-induced behaviours is intriguing, CGS 21680 showed a functional anti-dopaminergic effect in Cebus apella monkeys without production of EPS. This further substantiates that adenosine A2A receptor agonists may have potential as antipsychotics with atypical profiles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / adverse effects
  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology*
  • Amphetamine / antagonists & inhibitors
  • Amphetamine / pharmacology
  • Animals
  • Antipsychotic Agents*
  • Apomorphine / antagonists & inhibitors
  • Apomorphine / pharmacology
  • Arousal / drug effects
  • Basal Ganglia Diseases / chemically induced
  • Basal Ganglia Diseases / psychology
  • Behavior, Animal / drug effects*
  • Cebus
  • Conscious Sedation
  • Dopamine Agonists / pharmacology
  • Dopamine Antagonists / pharmacology
  • Dopamine Uptake Inhibitors / antagonists & inhibitors
  • Dopamine Uptake Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • Male
  • Motor Activity / drug effects
  • Phenethylamines / adverse effects
  • Phenethylamines / pharmacology*
  • Purinergic P1 Receptor Agonists*
  • Receptor, Adenosine A2A
  • Stereotyped Behavior / drug effects

Substances

  • Antipsychotic Agents
  • Dopamine Agonists
  • Dopamine Antagonists
  • Dopamine Uptake Inhibitors
  • Phenethylamines
  • Purinergic P1 Receptor Agonists
  • Receptor, Adenosine A2A
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Amphetamine
  • Adenosine
  • Apomorphine